406 related articles for article (PubMed ID: 29691297)
1. Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies.
Odegaard JI; Vincent JJ; Mortimer S; Vowles JV; Ulrich BC; Banks KC; Fairclough SR; Zill OA; Sikora M; Mokhtari R; Abdueva D; Nagy RJ; Lee CE; Kiedrowski LA; Paweletz CP; Eltoukhy H; Lanman RB; Chudova DI; Talasaz A
Clin Cancer Res; 2018 Aug; 24(15):3539-3549. PubMed ID: 29691297
[No Abstract] [Full Text] [Related]
2. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
[No Abstract] [Full Text] [Related]
3. Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel.
Willis J; Lefterova MI; Artyomenko A; Kasi PM; Nakamura Y; Mody K; Catenacci DVT; Fakih M; Barbacioru C; Zhao J; Sikora M; Fairclough SR; Lee H; Kim KM; Kim ST; Kim J; Gavino D; Benavides M; Peled N; Nguyen T; Cusnir M; Eskander RN; Azzi G; Yoshino T; Banks KC; Raymond VM; Lanman RB; Chudova DI; Talasaz A; Kopetz S; Lee J; Odegaard JI
Clin Cancer Res; 2019 Dec; 25(23):7035-7045. PubMed ID: 31383735
[TBL] [Abstract][Full Text] [Related]
4. Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma.
Verma S; Moore MW; Ringler R; Ghosal A; Horvath K; Naef T; Anvari S; Cotter PD; Gunn S
BMC Cancer; 2020 Oct; 20(1):945. PubMed ID: 33004033
[TBL] [Abstract][Full Text] [Related]
5. Analytical and clinical validation of an amplicon-based next generation sequencing assay for ultrasensitive detection of circulating tumor DNA.
Poh J; Ngeow KC; Pek M; Tan KH; Lim JS; Chen H; Ong CK; Lim JQ; Lim ST; Lim CM; Goh BC; Choudhury Y
PLoS One; 2022; 17(4):e0267389. PubMed ID: 35486650
[TBL] [Abstract][Full Text] [Related]
6. Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients.
Schwaederle M; Husain H; Fanta PT; Piccioni DE; Kesari S; Schwab RB; Patel SP; Harismendy O; Ikeda M; Parker BA; Kurzrock R
Clin Cancer Res; 2016 Nov; 22(22):5497-5505. PubMed ID: 27185373
[TBL] [Abstract][Full Text] [Related]
7. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.
Volckmar AL; Sültmann H; Riediger A; Fioretos T; Schirmacher P; Endris V; Stenzinger A; Dietz S
Genes Chromosomes Cancer; 2018 Mar; 57(3):123-139. PubMed ID: 29205637
[TBL] [Abstract][Full Text] [Related]
8. Statistical analysis of mutant allele frequency level of circulating cell-free DNA and blood cells in healthy individuals.
Xia L; Li Z; Zhou B; Tian G; Zeng L; Dai H; Li X; Liu C; Lu S; Xu F; Tu X; Deng F; Xie Y; Huang W; He J
Sci Rep; 2017 Aug; 7(1):7526. PubMed ID: 28790338
[TBL] [Abstract][Full Text] [Related]
9. Methods for Measuring ctDNA in Lymphomas.
Rossi D; Condoluci A; Spina V; Gaidano G
Methods Mol Biol; 2019; 1881():253-265. PubMed ID: 30350211
[TBL] [Abstract][Full Text] [Related]
10. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants.
Razavi P; Li BT; Brown DN; Jung B; Hubbell E; Shen R; Abida W; Juluru K; De Bruijn I; Hou C; Venn O; Lim R; Anand A; Maddala T; Gnerre S; Vijaya Satya R; Liu Q; Shen L; Eattock N; Yue J; Blocker AW; Lee M; Sehnert A; Xu H; Hall MP; Santiago-Zayas A; Novotny WF; Isbell JM; Rusch VW; Plitas G; Heerdt AS; Ladanyi M; Hyman DM; Jones DR; Morrow M; Riely GJ; Scher HI; Rudin CM; Robson ME; Diaz LA; Solit DB; Aravanis AM; Reis-Filho JS
Nat Med; 2019 Dec; 25(12):1928-1937. PubMed ID: 31768066
[TBL] [Abstract][Full Text] [Related]
11. Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA.
Clark TA; Chung JH; Kennedy M; Hughes JD; Chennagiri N; Lieber DS; Fendler B; Young L; Zhao M; Coyne M; Breese V; Young G; Donahue A; Pavlick D; Tsiros A; Brennan T; Zhong S; Mughal T; Bailey M; He J; Roels S; Frampton GM; Spoerke JM; Gendreau S; Lackner M; Schleifman E; Peters E; Ross JS; Ali SM; Miller VA; Gregg JP; Stephens PJ; Welsh A; Otto GA; Lipson D
J Mol Diagn; 2018 Sep; 20(5):686-702. PubMed ID: 29936259
[TBL] [Abstract][Full Text] [Related]
12. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin.
Woodhouse R; Li M; Hughes J; Delfosse D; Skoletsky J; Ma P; Meng W; Dewal N; Milbury C; Clark T; Donahue A; Stover D; Kennedy M; Dacpano-Komansky J; Burns C; Vietz C; Alexander B; Hegde P; Dennis L
PLoS One; 2020; 15(9):e0237802. PubMed ID: 32976510
[TBL] [Abstract][Full Text] [Related]
13. Automated size selection for short cell-free DNA fragments enriches for circulating tumor DNA and improves error correction during next generation sequencing.
Hellwig S; Nix DA; Gligorich KM; O'Shea JM; Thomas A; Fuertes CL; Bhetariya PJ; Marth GT; Bronner MP; Underhill HR
PLoS One; 2018; 13(7):e0197333. PubMed ID: 30044795
[TBL] [Abstract][Full Text] [Related]
14. Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA.
Lanman RB; Mortimer SA; Zill OA; Sebisanovic D; Lopez R; Blau S; Collisson EA; Divers SG; Hoon DS; Kopetz ES; Lee J; Nikolinakos PG; Baca AM; Kermani BG; Eltoukhy H; Talasaz A
PLoS One; 2015; 10(10):e0140712. PubMed ID: 26474073
[TBL] [Abstract][Full Text] [Related]
15. A high-throughput protocol for isolating cell-free circulating tumor DNA from peripheral blood.
Pandoh PK; Corbett RD; McDonald H; Alcaide M; Kirk H; Trinh E; Haile S; MacLeod T; Smailus D; Bilobram S; Mungall AJ; Ma Y; Moore RA; Coope R; Zhao Y; Jones SJ; Holt RA; Karsan A; Morin RD; Marra MA
Biotechniques; 2019 Feb; 66(2):85-92. PubMed ID: 30744412
[TBL] [Abstract][Full Text] [Related]
16. False-Positive Plasma Genotyping Due to Clonal Hematopoiesis.
Hu Y; Ulrich BC; Supplee J; Kuang Y; Lizotte PH; Feeney NB; Guibert NM; Awad MM; Wong KK; Jänne PA; Paweletz CP; Oxnard GR
Clin Cancer Res; 2018 Sep; 24(18):4437-4443. PubMed ID: 29567812
[No Abstract] [Full Text] [Related]
17. Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial.
Jovelet C; Ileana E; Le Deley MC; Motté N; Rosellini S; Romero A; Lefebvre C; Pedrero M; Pata-Merci N; Droin N; Deloger M; Massard C; Hollebecque A; Ferté C; Boichard A; Postel-Vinay S; Ngo-Camus M; De Baere T; Vielh P; Scoazec JY; Vassal G; Eggermont A; André F; Soria JC; Lacroix L
Clin Cancer Res; 2016 Jun; 22(12):2960-8. PubMed ID: 26758560
[TBL] [Abstract][Full Text] [Related]
18. Discrimination of Germline
Hu Y; Alden RS; Odegaard JI; Fairclough SR; Chen R; Heng J; Feeney N; Nagy RJ; Shah J; Ulrich B; Gutierrez M; Lanman RB; Garber JE; Paweletz CP; Oxnard GR
Clin Cancer Res; 2017 Dec; 23(23):7351-7359. PubMed ID: 28947568
[No Abstract] [Full Text] [Related]
19. Using plasma cell-free DNA to monitor the chemoradiotherapy course of cervical cancer.
Tian J; Geng Y; Lv D; Li P; Cordova M; Liao Y; Tian X; Zhang X; Zhang Q; Zou K; Zhang Y; Zhang X; Li Y; Zhang J; Ma Z; Shao Y; Song L; Owen GI; Li T; Liu R; Liu Q; Zou L; Zhang Z; Li Z
Int J Cancer; 2019 Nov; 145(9):2547-2557. PubMed ID: 30919951
[TBL] [Abstract][Full Text] [Related]
20. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer.
Liu L; Liu H; Shao D; Liu Z; Wang J; Deng Q; Tang H; Yang H; Zhang Y; Qiu Y; Cui F; Tan M; Zhang P; Li Z; Liu J; Liang W; Wang Y; Peng Z; Wang J; Yang H; Mao M; Kristiansen K; Ye M; He J
Genes Chromosomes Cancer; 2018 Apr; 57(4):211-220. PubMed ID: 29277949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
